newsfilter
← Earnings
Earnings Releases·

Apnimed — Third Quarter 2026 Earnings Summary

  • Reported net loss of $29.5 million for Q3 2026, widening from $10.9 million in the prior year period, driven by a 100%+ increase in G&A expenses to $22.6 million and a 20% rise in R&D to $11.8 million.
  • Achieved a transformative balance sheet position with cash and equivalents rising to $351.8 million from $41.9 million following an August 2026 IPO raising $198.9 million net proceeds, while total liabilities decreased to $86.7 million and equity turned positive at $284.8 million.
  • NDA for AD109 (Oxnimbi) remains under FDA review with a PDUFA goal date of February 28, 2027; current cash reserves are projected to fund U.S. launch preparations and operations through Q2 2028.
  • Revenue from related parties declined to $2.5 million from $8.8 million year-over-year, while other income surged to $2.7 million from $0.3 million due to interest income and fair value changes in long-term debt.
Company
APNIMED INC
Sector
Healthcare
Industry
Biotechnology